Hernández Yicel Bautista, Herrera Valeria Vazquez, Gómez Karina Vázquez, Martinez Ana Laura Lopez
Radiotherapy Department, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico.
National Medical Center "20 de Noviembre ISSSTE", Ciudad de México, Mexico.
Rep Pract Oncol Radiother. 2025 Aug 7;30(3):345-351. doi: 10.5603/rpor.106150. eCollection 2025.
Paragangliomas are highly vascularized tumours that have benign histology, with malignant dissemination being infrequent (< 5%). Surgery is the only option offering complete resection; however, there is significant morbidity. Treatment with radiotherapy (RT) offers good results in controlling the disease.
Retrospective, observational and descriptive study from the RT Service of the General Hospital of Mexico conducted from January 1, 2016 to January 1, 2021 that included patients with carotid paraganglioma in whom RT response was evaluated by determining clinical and image size at the beginning of the study and end of follow-up. Correlation of response to treatment, and toxicity related to RT, were analysed.
55 patients were included, 92.7% were female, the mean age was 58.7 years, and the mean follow-up time was 28.87 months. The mean initial clinical size was 4.75 cm. Initial imaging study mean size was 4.76 cm. A total of 92.7% received intensity-modulated radiotherapy (IMRT) and conformal RT (7.3%), mean prescribed dose was 51.90 Gy (50-54), with a median of 50.4 Gy/25 fractions. The mean final clinical size was 3 cm. The final imaging study mean size was 3.48 cm. At the end of the study, 96.4% showed a response to treatment and 3.6% progressed. Analysis showed no significance between treatment response and RT dose (p < 0.5) or between RT response and the % dose to the planned treatment volume (PTV) (p = 0.91). Acute toxicity was found in 55 patients, with grade 1 radiodermatitis, and chronic toxicity in 44 patients, with atrophy grade 1.
RT represents a therapeutic option in the management of patients with carotid paraganglioma because it offers a high probability of local control, without toxicity.
副神经节瘤是血管高度丰富的肿瘤，组织学表现为良性，恶性播散罕见（<5%）。手术是实现完全切除的唯一选择；然而，手术并发症发生率较高。放射治疗（RT）在控制该疾病方面效果良好。
对墨西哥总医院放疗科2016年1月1日至2021年1月1日进行的一项回顾性、观察性和描述性研究进行分析，该研究纳入了颈动脉副神经节瘤患者，通过在研究开始时和随访结束时确定临床和影像大小来评估RT反应。分析治疗反应与RT相关毒性之间的相关性。
纳入55例患者，92.7%为女性，平均年龄58.7岁，平均随访时间28.87个月。初始临床平均大小为4.75 cm。初始影像学研究平均大小为4.76 cm。共有92.7%的患者接受了调强放疗（IMRT），7.3%接受了适形放疗，平均处方剂量为51.90 Gy（50 - 54），中位剂量为50.4 Gy/25次分割。最终临床平均大小为3 cm。最终影像学研究平均大小为3.48 cm。研究结束时，96.4%的患者显示对治疗有反应，3.6%病情进展。分析表明治疗反应与RT剂量之间无显著差异（p < 0.5），RT反应与计划治疗体积（PTV）的剂量百分比之间也无显著差异（p = 0.91）。55例患者出现急性毒性，表现为1级放射性皮炎，44例患者出现慢性毒性，表现为1级萎缩。
RT是颈动脉副神经节瘤患者管理中的一种治疗选择，因为它提供了较高的局部控制概率且无毒性。
